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Summary
RAL small GTPases, encoded by the Rala and Ralb genes,
are members of the RAS superfamily of small GTPases and
can act as downstream effectors of RAS [1]. Although highly
similar, distinct functions have been identified for RALA and
RALB: RALA has been implicated in epithelial cell polarity
[2], insulin secretion [3], GLUT4 translocation [4, 5], neurite
branching, and neuronal polarity [6, 7], and RALB in tumor
cell survival [8], migration/invasion [9–12], TBK1 activation
[13], and autophagy [14]. To investigate RAL GTPases
in vivo, we generated null and conditional knockout mice.
Ralb null mice are viable with no overt phenotype; the Rala
null leads to exencephaly and embryonic lethality. The exen-
cephaly phenotype is exacerbated in Rala2/2;Ralb+/2
embryos; embryos null for Rala and Ralb do not live past
gastrulation. Using a Kras-driven non-small cell lung carci-
noma mouse model, we found that either RALA or RALB is
sufficient for tumor growth. However, deletion of both Ral
genes blocks tumor formation. Either RALA or RALB is
sufficient for cell proliferation, but cells lacking both fail to
proliferate. These studies demonstrate functions of RAL
proteins in development, tumorigenesis, and cell prolifera-
tion and show that RALA and RALB act in a redundant
fashion.
Results and Discussion
RAL Small GTPases Are Required for Neural Tube Closure
in the Mouse
To investigate the functions of RAL GTPases in mouse devel-
opment and tumorigenesis, we generated null and conditional
alleles of the Rala and Ralb loci using the Cre-lox system. The
Rala and Ralb genes have similar intron-exon structures, with
five exons and the translation start site located in exon 2. We
flanked exons 2 and 3 in Rala and exon 2 in Ralb with LoxP
sites (see Figures S1A–S1D available online). To obtain null
alleles, mice carrying the targeted alleles were crossed to the
PGK-Cre transgenic strain. Intercrossing Ralb+/2 mice gener-
ated Ralb null pups at the expected Mendelian ratio that were
viable, displayed no obvious abnormalities (Figure 1D), and
developed to fertile adults. Rala+/2 intercrosses did not
generate Rala null mice, implying that Rala is required for
embryonic development. We confirmed the loss of RALA and
RALB proteins in null mouse embryonic fibroblasts (MEFs)*Correspondence: chris.marshall@icr.ac.uk(Figures 1A and 1B) and loss of RALB proteins in tissues of
adult mice (Figure 1C). The expression of RALB proteins was
unchanged in Rala null cells and vice versa.
To investigate the role of RALA in embryonic development,
we examined embryos from Rala+/2 intercrosses. Between
embryonic day 10.5 (E10.5) and E19.5, we observed that 10
out of 33 of the Rala null embryos displayed exencephaly
(Figures 1E and 1F), a condition caused by a failure of closure
of the neural tube along the hindbrain region [15]. We also
observed exencephaly in Rala null embryos generated from
a gene-trap embryonic stem (ES) clone (Figures 1G and S1E–
S1I). To examine whether RALA and RALB have overlapping
functions in neural tube closure, we generated compound
mutants: 14 of 14 Rala2/2;Ralb+/2 embryos displayed a severe
neural tube defect (NTD) at E10.5–E13.5, with open neural tube
at the forebrain/midbrain boundary and hindbrain/cervical
boundary, as well as caudally (Figures 1H–1J). These embryos
also exhibited developmental retardation. We did not observe
NTDs in Rala+/2;Ralb2/2 embryos (0 of 8), although some of
them displayed developmental retardation. These observa-
tions demonstrate a role for RALA during neural tube closure
that can only be partially compensated by RALB. Importantly,
we failed to identify Rala2/2;Ralb2/2 embryos between E10.5
and E13.5, establishing that RALA and RALB share functions
that are essential during early embryogenesis (Figure 1J). In
further support of the conclusion that RALA and RALB have
overlapping functions, we found that when the Ral-floxed
alleles were crossed to an adipocyte-specific Cre [16],
absence of either RALA or RALB in adipocytes had no effect
on viability, but absence of both RAL proteins led to perinatal
lethality (data not shown).
RALA and RALB Act Redundantly in RAS-Driven
Tumorigenesis
To investigate the functions of RALA and RALB in RAS-medi-
ated tumorigenesis, we crossed the Ral-targeted mice to the
LSL-KrasG12D non-small cell lung carcinoma (NSCLC) model,
where the expression of an oncogenic allele of Kras requires
the excision of a LoxP-stop-LoxP cassette by Cre recombi-
nase [17]. This mouse model develops tumors that are histo-
logically similar to human adenocarcinoma, 30% of which
harbor KRAS mutations [18].
Because Rala null mice exhibit embryonic lethality, we used
mice with two copies of the Ralalox conditional allele so that
excision of Rala only occurred in lung epithelial cells express-
ing Cre recombinase. Because Ralb null mice are viable, we
used null (Ralb2/2) and conditional (Ralblox/2) alleles. Cohorts
were treated with adenovirus expressing Cre (AdCre) and
sacrificed 6 months later [17, 19]. Histological analysis re-
vealed a similar number of tumors and tumor grade distribu-
tion among WT, Ralalox/lox, Ralblox/2, and Ralb2/2 animals
(Figures 2A and 2D).Wequantified tumor burden bymeasuring
the volume of lesions via microcomputed tomography (mi-
croCT) imaging, which revealed no significant difference
between the genotypes (Figure 2G). To show whether Ralalox
alleles were efficiently recombined in tumors, we performed
immunohistochemistry (IHC) on lung cross-sections with an
anti-RALA antibody (Figures 2E and 2F); 80% of tumors in
Figure 1. RAL GTPases Are Required for Mouse Embryonic Development
(A–C) Western blot analysis of RALA and RALB protein expression in Rala2/2 (A) and Ralb2/2 (B) MEFs and in tissues from Ralb2/2 mice (C).
(D) Offspring from Ralb+/2 intercrosses were genotyped 3 weeks after birth.
(E) Embryos from Rala+/2 intercrosses were collected between E9.5 and E19.5 and examined for the presence of neural tube defects (NTDs).
(F and G) Images of Rala null embryos generated either by gene targeting (F) or gene trap (GT) (G) displaying exencephaly beside a control littermate.
(H and I) Images of Rala2/2;Ralb+/2 embryos. Arrows indicate where the neural tube remained open.
(J) Analysis of embryos dissected between E10.5 and E13.5 from either Rala+/2;Ralb2/2 3 Rala+/2;Ralb+/2 or Rala+/2;Ralb+/2 3 Rala+/2;Ralb+/2 crosses.
Embryos were scored for NTDs and somite count and then genotyped.
See also Figure S1.
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2064Ralalox/lox mice had completely lost RALA expression (Fig-
ure 2H). Hence, the absence of RALA or RALB does not affect
the formation of NSCLC. We obtained similar results using
the 7,12-dimethylbenzanthracene-12-O-tetradecanoylphorbol-
13-acetate (DMBA-TPA)-induced, Hras-driven skin carcino-
genesis tumor model [20] using Ralb null mice or K14-Cre
[21] and Ralalox/lox alleles to specifically excise Rala from the
epidermis; in both cases, tumor formation was not impaired
(Figure S3).
Because the deletion of either Rala or Ralb has no apparent
effect on the formation of NSCLC, we tested whether deleting
both RAL GTPases would impair NSCLC formation. Mice with
aKrasG12D;Ralalox/lox;Ralb2/2 genotype had fewer tumors than
their control KrasG12D;Ralalox/+;Ralb2/2 littermates (Figures 3A
and 3B). Histological analysis showed a 60% decrease in
tumor area (Figure 3E). Similarly, quantification of tumor
burden by microCT showed a 60% decrease in KrasG12D;
Ralalox/lox;Ralb2/2 mice (Figure 3F). In marked contrast to
tumors inKrasG12D;Ralalox/lox animals (Figure 2H), we observed
that RALA was expressed in all tumors arising in KrasG12D;
Ralalox/lox;Ralb2/2 mice (Figures 3D and 3G). These data
show that RAL function is essential for tumorigenesis in this
NSCLC model, the expression of either RALA or RALB being
sufficient.
Redundant Activity of RALA and RALB in Cell Proliferation
To investigate whether the requirement for RAL GTPases
in tumor formation reflects a role in cell proliferation, we gener-
ated Rala2/2, Ralb2/2, and Ralalox/lox;Ralb2/2 MEFs andexamined their ability to proliferate. Rala and Ralb null MEFs
proliferated as well as their WT counterparts (Figure 4A). To
rule out selection for a compensatory mechanism during
embryogenesis, we infected Ralalox/lox and Ralblox/lox MEF
populations with adenovirus expressing Cre and green fluo-
rescent protein (AdCreGFP) and observed that they pro-
liferated as well as their counterparts infected with adenovirus
expressing GFP alone (data not shown). However, three inde-
pendent populations of Ralalox/lox;Ralb2/2 MEFs infected with
AdCreGFP viruses failed to proliferate (Figure 4B). The effi-
ciency of excision was confirmed by western blotting (Fig-
ure 4C). Hence, deletion of both RAL GTPases seriously
impairs the ability of MEFs to proliferate. We assume that
the proliferating cells in the AdCreGFP-infected Ralalox/lox;
Ralb2/2 MEF population retained RALA expression. Consis-
tent with this, although we were able to select WT MEF popu-
lations stably expressing Cre recombinase using a retrovirus
encoding Cre, we were unable to do this with Ralalox/lox;
Ralb2/2 MEFs.
We have shown that RAL function is essential for cell prolif-
eration, but the fact that either RALA or RALB is sufficient
implies that they act redundantly. This redundancy raises the
issue of whether there is compensatory activation of a RAL
isoform in the absence of the other isoform; therefore, we
measured the amount of activated GTP-loaded RALB in Rala
null MEFs and vice versa. We observed that RALB-GTP was
significantly increased in Rala null MEFs (Figures 4D and 4E)
and that RALA-GTP was increased in Ralb null MEFs (Figures
4F and 4G). This increase in activation occurred without any
Figure 2. RALA and RALB Are Not Singly Required for KrasG12D-Induced NSCLCs
Cohorts of mice carrying one LSL-KrasG12D allele and the indicatedRal alleles were treated once with adenoCre viruses by intranasal instillation. Six months
later, the mice were sacrificed and the lungs processed for histological and microCT analysis.
(A–D) Hematoxylin and eosin (H&E) staining of lung sections from mice of the indicated genotype.
(E and F) Immunohistochemistry (IHC) performed using an antibody against RALA on lung sections (43 magnification).
(G) Quantification of the tumor burden in the lungs of the mice of the indicated genotypes. Left lobes were processed for microCT scanning, and the ratio of
total tumor volume to total lung volume was measured for each animal; mean 6 SD.
(H) Tumors in Ralalox/lox mice were scored for RALA protein expression using images as shown in (F); 97 tumors from 8 animals were scored.
See also Figure S2.
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2065apparent increase in the level of RAL proteins (Figures 4D
and 4F). We obtained similar results using MEFs carrying
Ral-floxed alleles infected with AdCreGFP (data not shown).
Hence, the loss of one RAL protein is partially compensated
by an increase in the activation of the other isoform, suggest-
ing that it is the overall level of RAL activity that is important
rather than a specific isoform.
The different functions ascribed to RALA and RALB have
been rationalized in part by different subcellular localizations
[2, 22]. To investigate subcellular localization, we generated
HeLa and MEF cell populations stably coexpressing
mCherry-RALA and GFP-RALB at levels similar to the endog-
enous proteins. In both cell types, most RALA and RALB
proteins colocalize at interphase (HeLa, thresholded Pear-
son’s correlation coefficient [PCC] > 0.600), the majority of
RAL proteins being present at the plasma membrane while
a fraction are on intracellular puncta, as previously reported
(HeLa, Figure S4; MEFs, data not shown) [2, 23, 24]. However,
every cell examined displayed intracellular structures that
were positive for RALA but not RALB. The identity of the struc-
tures remains to be determined. Interestingly, an even higher
fraction of RALA and RALB proteins colocalized during the
different stages of mitosis (HeLa, thresholded PCC > 0.750)
(Figure S4).
Vertebrate Rala and Ralb genes derive from a common
ancestor in metazoa and fungi, Rala being most similar to its
metazoan orthologs [25]. Despite the high similarity between
RALA and RALB proteins, many studies have attributeddifferent functions to the isoforms. However, no previous
work has used rigorous germline approaches; therefore, to
investigate the role of RALA and RALB in mouse development
and tumorigenesis, we generated null and conditional alleles.
We found that RALA but not RALB is required for embryonic
development, implying that RALA has a unique role. Ralb null
mice develop apparently normally and are viable and fertile.
Nearly 30% of Rala null embryos displayed exencephaly;
100% of Rala2/2;Ralb+/2 embryos displayed a more severe
NTD. This indicates that RALA has a specific function in neural
tube closure but that RALB is also involved. Possibly the
unique requirement for RALA may reflect differences in
expression rather than protein function, although it has been
reported that both Ral genes have very similar expression
patterns between E9.5 and E16.5 [26].
Strikingly, we observed that either RALA or RALB is suffi-
cient for proliferation of MEFs in culture but that deletion of
both Rala and Ralb blocks proliferation. Together with the
more severe NTD in Rala2/2; Ralb+/2 embryos, these data
argue for overlapping, redundant functions of RAL proteins.
The requirement for RAL GTPases for cell proliferation may
explain the early lethality of the Rala2/2;Ralb2/2 embryos
because no embryos were present at E10.5. The redundancy
of RAL GTPases in cell proliferation that we observed
contrasts with a reported nonredundant function during
cytokinesis, where HeLa cells depleted of RALA and RALB
have a binucleated phenotype similar to cells depleted of
RALA only [27]. The fact that a cell proliferation defect was
Figure 3. Ablation of Both RALA and RALB Impairs the Formation of NSCLCs
Comparison of tumor formation in KrasG12D;Ralalox/+;Ralb2/2 and KrasG12D;Ralalox/lox;Ralb2/2 mice. The experiment was conducted as in Figure 2.
(A and B) H&E staining of two representative lung sections of the indicated genotype.
(C and D) IHC against RALA on sections from KrasG12D;Ralalox/+;Ralb2/2 (C) and KrasG12D;Ralalox/lox;Ralb2/2 (D) animals (43 magnification).
(E) Quantification of tumor burden by measuring the area of tumors and total area of lungs on serial cross-sections of the right lobes; mean 6 SD.
(F) Quantification of tumor burden by microCT as described in Figure 2G; mean 6 SD, representative of three independent experiments (n R 7 for each
genotype in each experiment).
(G) Tumors in KrasG12D;Ralalox/lox;Ralb2/2 mice were scored for RALA protein expression; 40 tumors from 8 animals.
See also Figure S3.
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complete depletion of RAL proteins is required to reveal this
phenotype. MEFs lacking expression of all three RAS genes
do not proliferate but can be rescued by expression of consti-
tutive activation of RAF, but not RAL [28]. This suggests that
RAF activation is the key signaling event downstream of RAS
for proliferation of MEFs. Because our results show that RAL
is also required for proliferation of MEFs, they argue that
RAL activation is not downstream of RAS signaling in cell
proliferation.
A number of studies suggest that RALA and RALB have
distinct roles in cancer cells, RALA being required for tumor
cell proliferation and RALB for tumor cell survival and migra-
tion [1]. These studies used RNAi in human cancer cell culture
models of pancreatic [9], bladder, and prostate origin [10, 12].
More recently, a requirement for RALA in cell proliferation and
survival was shown in human NSCLC cells [29]. Hence, we
were surprised to discover that the deletion of either Rala or
Ralb does not impair the formation of KRASG12D-driven tumors
in amousemodel of NSCLC. Similarly, we observed that tumor
formation was not compromised in the absence of either
RALA or RALB in DMBA-TPA-induced skin carcinogenesis or
a mouse model of KRASG12D-driven pancreatic adenocarci-
noma (J. Morton, O. Sansom, P.P., and C.J.M., unpublished
data). The discrepancy between these results and the RNAi-
based experimentsmay be due to the fact that in RNAi studies,
RAL is depleted in fully transformed cells, whereas in our
genetic system, the Ral gene is deleted at tumor initiation,
possibly allowing time for adaptation and compensation
during the process of cell transformation. However, if such
adaptation is the explanation for the difference between our
genetic experiments and RNAi studies, it reinforces theargument that RALA and RALB have redundant functions in
tumorigenesis. It will be necessary to induce the genetic
deletion of Rals in established tumors to gain further insight
into their role in tumor maintenance and to study the require-
ment for RAL GTPases in the formation of tumors that are
not driven by oncogenic RAS.
Overall, this work reveals new roles for RAL GTPases during
embryonic development and cell proliferation. Our data
strongly support the conclusion that much of RAL signaling
can be performed by either RALA or RALB.
Experimental Procedures
Plasmids and Reagents
Adenoviruses were obtained from the Gene Transfer Vector Core at the
University of Iowa. We used the following primary antibodies: Rala (BD
Biosciences, 610222), Ralb (LifeSpan BioSciences, LS-C38719; SCBT,
SC-1531; Millipore, 04-037), and GAPDH (Novus Biologicals, NB300-221).
Human RALA (GC-Z1257) and RALB (GC-B0022) cDNAs were obtained
from GeneCopoeia and transferred using Gateway Technology into pLVX-
puro lentiviral vectors (Clontech) containing either enhanced GFP or
mCherry (kind gift of Jasmine Abella) and the RfC.1 Gateway cassette
(Invitrogen). Lentiviruses were produced in 293T cells cotransfected
with pMD2.G and psPAX2 packaging vectors (http://tronolab.epfl.ch/
lentivectors).
Mice
The targeting vectors to generate the Rala and Ralb gene-targeted mice
were made by inserting the arms of homology into the pGKNeoF2L2FDTA
vector (Phillipe Soriano, Addgene plasmid 13445 [30]). The homologous
recombination was performed in Bruce4 ES cells of C57BL/6J origin
(Ozgene). The positive clones were identified by PCR and confirmed by
Southern blotting before being injected into albino C57BL/6J blastocysts
to generate chimeras in a pure C57BL/6J background. The Rala- and
Ralb-targeted mice were crossed to the PGK-Neo or PGK-Flp transgenic
Figure 4. MEFs Null for Rala and Ralb Fail to Proliferate
(A and B) Proliferation curves. Cells (5.53 103/cm2) were seeded in triplicate and counted daily for 3 days. Each point represents the average6 SEM of three
independent experiments. In (A), two independent MEF populations were used in each experiment. In (B), three independent Ralalox/lox;Ralb2/2MEF pop-
ulations Pop1 (population 1), Pop2 (population 2), and Pop3 (population 3) were infected with either adenoCre or adenoCreGFP and seeded 3 days later for
the proliferation assay.
(C) Western blot analysis performed with lysates from adeno-infected (Ad) Ralalox/lox;Ralb2/2MEF populations collected at day 1 of the proliferation assay.
The membrane was probed with anti-RALA and anti-GAPDH antibodies.
(D) Western blot analysis showing the levels of RALB-GTP and total RALB in two independent populations of WT and Rala2/2MEFs cultured in 10% serum.
(E) Quantification of western blots of three independent experiments; mean 6 SD (**p% 0.01).
(F) Levels of RALA-GTP and total RALA in two independent populations of WT and Ralb2/2 MEFs.
(G) Quantification of data from (F), as in (E); mean 6 SD.
See also Figure S4.
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2067mice (provided by the Cancer Research UK transgenic facility) to generate
the knockout and conditional knockout mice, respectively. The DD1113
Rala gene-trap ES clone was obtained from the Sanger Institute, and the
mice were derived at the Cancer Research UK transgenic facility. Images
of embryos were captured using a M2FLIII microscope and DC500 camera
(Leica Microsystems). The LSL-KrasG12Dmice were a generous gift of Dave
Tuveson [31]. The lung tumor experiments were performed on mice with
a pure C57BL/6J genetic background. Briefly, the mice were anesthetized
with ketamine and xylazine and treated once by intranasal instillation using
either 0.5 or 13 108 pfu/mouse of adenoCre viruses as described in [19]. For
the DMBA-TPA-induced skin carcinogenesis experiment, the K14-Cremice
(FVB-Tg(K14-Cre)8Brn) [32] were acquired from the National Cancer
Institute Mouse Models of Human Cancers Consortium, and the Ral mice
were backcrossed in a FVB/N genetic background for at least six genera-
tions. The animals were shaved and treated topically with a single dose of
7,12-dimethylbenzanthracene (DMBA, Sigma-Aldrich) followed by 12-O-
tetradecanoylphorbol-13-acetate (TPA, Sigma-Aldrich) twice weekly for
20 weeks as described in [33]. The FABP4-Cre (AP2-Cre) mice [16] used
to delete floxed Ral alleles in adipocytes were obtained from the Institute
of Metabolic Science at the University of Cambridge. Animals were handled
in strict accordancewith UKHomeOffice regulations and institutional ethics
approval.
Histopathology and Immunohistochemistry
Lungs were perfused and fixed in 10% buffered formalin for 24 hr. The right
lobes were embedded in paraffin, and the left lobe was processed for mi-
croCT imaging. For IHC against RALA, paraffin sections were pretreated
for 2 min in a pressure cooker in citrate buffer (pH 6), washed, blocked
1 hr in mouse IgG block (VECTASTAIN) and then 5 min in protein block
(Dako X0909), incubated 1 hr with anti-RALA antibody (1:250; BD Biosci-
ences, 610222), washed, incubated 30 min in Mouse EnVision (Dako),
washed, incubated 5 min in diaminobenzene, washed, and counterstained
with Gill’s hematoxylin. The washes were all performed using Dako FLEX
Wash Buffer (K8000). The RALA antibody was validated for IHC with WTand Rala null MEFs that were formalin fixed and paraffin embedded
(Figure S1I).
MicroCT Analysis
After being fixed in formalin, lungs were dehydrated in ethanol (35%, 2 hr;
70%, 2 hr; 80%, 2 hr; 90%, 2 hr; 100%, 12 hr), transferred to hexamethyldisi-
lazane (Sigma-Aldrich, #52619) for 2 hr, and dried for 12 hr. The lungs were
scanned in a SkyScan 1076 microCT scanner (Bruker microCT) with the
following settings: Styrofoam bed, no filter, 18 mm resolution, 40 kV, 120 ms
exposure, and0.4 rotationstep.Thescanswere reconstructedandanalyzed
using NRecon and CTAn software, respectively (Bruker microCT).
Cell Culture and Pull-Down Assays
MEFs were isolated from E13.5 embryos and cultured in a low-oxygen (3%)
incubator [34] in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum. For analysis of RAL-GTP levels, 1 3 106 cells were lysed in
650 ml of ice-cold Ral lysis buffer (50 mM Tris [pH 7.4], 10% glycerol, 1%
NP40, 5 mM MgCl2, 100 mM NaCl, 1 mM dithiothreitol [DTT], and cOmplete
EDTA-free Protease Inhibitor; Roche). The lysates were spun at 13,000 rpm
at 4C for 15 min. Next, 400 ml of the supernatant was incubated with 25 ml
of glutathione Sepharose beads bound to approximately 50 mg glutathione
S-transferase-RalBP1 RBD proteins at 4C for 45 min. The beads were
spun at 4C for 5 min at 1,000 3 g and washed twice with 1 ml of Ral wash
buffer (Tris-buffered saline, 10 mM MgCl2, 1 mM DTT, and cOmplete EDTA-
free Protease Inhibitor) before being resuspended in Laemmli loading buffer
containing 100 mM DTT. Immunoblotting analyses were performed using
anOdyssey ImagingSystem(LI-CORBiosciences)according to themanufac-
turer’s instructions.Confocal imageswereacquiredwithaZeissLSM7micro-
scope, and imageswereprocessedandanalyzedwithVolocity (PerkinElmer).
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